MapLight Therapeutics, Inc.
ML-004
autism spectrum disorder
Resolved
15days ago
Phase 2 readout · Jun 22, 2026
What's at stake
Phase 2 trial results for ML-004 in autism spectrum disorder are due Jun 22, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 13h ago
“On June 22, 2026, MapLight Therapeutics, Inc. (the “Company”) will hold a conference call to discuss the topline results from IRIS (ML-004-002), a Phase 2 study of ML-004 in autism spectrum disorder (the “IRIS Trial Results”).”